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Abstract
In this study we have identified a new structural
motif for a ligand with G-quadruplex interaction
that results in biological effects associated with G-
quadruplex-interactive compounds. Fluoroquinolones
have been reported to possess weak telomerase
inhibitory activity in addition to their better known
bacterial gyrase poisoning. Starting with a
fluoroquinobenzoxazine, which has modest potency
in a human topoisomerase II assay, we have
designed a more potent inhibitor of telomerase that
has lost its topoisomerase II poisoning activity.
This fluoroquinophenoxazine (FQP) interacts with
G-quadruplex structures to inhibit the progression
of Taq polymerase in a G-quadruplex polymerase
stop assay. In addition, we demonstrate by 1H NMR
studies that this compound interacts with telomeric
G-quadruplex structures by external stacking to the
G-tetrad with both the unimolecular fold-over and the
parallel G-quadruplex structures. A photocleavage assay
confirms the FQP interaction site, which is located off
center of the external tetrad but within the loop region.
Molecular modeling using simulated annealing was
performed on the FQP-parallel G-quadruplex complex to
determine the optimum FQP orientation and key
molecular interactions with the telomeric G-quadruplex
structure. On the basis of the results of these studies,
two additional FQP analogues were synthesized, which
were designed to test the importance of these key
interactions. These analogues were evaluated in the Taq
polymerase stop assay for G-quadruplex interaction. The
data from this study and the biological evaluation of
these three FQPs, using cytotoxicity and a sea urchin
embryo system, were in accord with the predicted more
potent telomeric G-quadruplex interactions of the initial
lead compound and one of the analogues. On the basis
of these structural and biological studies, the design of
more potent and selective telomeric G-quadruplex-
interactive compounds can be envisaged.
Introduction
Fluoroquinolones are best known therapeutically as bacterial
gyrase inhibitors (1, 2) but more recently have also been
demonstrated to be active against eukaryotic topoisomerase
II, either as catalytic inhibitors or topoisomerase II poisons
(3), or as telomerase inhibitors (4). One such group of com-
pounds, the quinobenzoxazines, typified by A-62176
(Fig. 1B), has served as a starting point for the design of more
potent topoisomerase II inhibitors using a structure-based
approach (5). The extended aromatic conjugation system of
A-62176 suggested to us that quinobenzoxazines may also
intercalate with the more expansive system of G-quadruplex
DNA and thereby be telomerase inhibitors in parallel with other
G-quadruplex-interactive compounds, such as the anthraqui-
nones (6–10), cationic porphyrins (11–13),9 piperazines (14),
ethidium compounds, (15), and a pentacyclicacridinium com-
pound (16). After we started this project, an independent report
that bacterial quinolones may be weak telomerase inhibitors (4)
also supported the idea that a ring-extended fluoroquinolone
would be a more potent telomerase inhibitor.
G-quadruplexes (Fig. 1A) were first identified in 1962 (17);
however, their possible biological significance was only sug-
gested starting in the late 1980s (18–23), and they were first
proposed to be potential targets for drug design in 1989 (24).
The existence of chaperone proteins that facilitate their for-
mation (25–27), G-quadruplex binding proteins that recog-
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nize these structures (25, 28–31), and G-quadruplex-selec-
tive helicases (32–34) that unwind these structures make
their existence in vivo in human cells a real possibility. Re-
cently their in vivo existence in ciliates has been supported
by antibody studies (35).
G-quadruplex-interactive compounds have aroused
more interest recently because it has been demonstrated
that these compounds not only inhibit telomerase in
cell-free (6, 9) and in in vitro systems (36) but also
cause telomere shortening and cell crisis in cancer cells
Fig. 1. A, G-tetrad and G-quadru-
plexes. Panel a, four guanine residues
forming a planar structure G-tetrad
through Hoogsteen hydrogen bond-
ing. Panel b, a parallel G-quadruplex
model. Panel c, an intermolecular anti-
parallel G-quadruplex model. Panel d,
an intramolecular basket G-quadru-
plex model. Each parallelogram in
panels b– d represents a G-tetrad.
B, structures of the topoisomerase
II-interactive compound (A-62176)
and G-quadruplex-interactive com-
pounds QQ58, QQ27, QQ28, and
TMPyP4.
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(14).10 A number of reviews on G-quadruplex and their targeting
by small molecules have appeared recently (37–45).
In this contribution we demonstrate that QQ58 (Fig. 1B), a
FQP11 that lacks bacterial gyrase or topoisomerase II poi-
soning activity, is able to bind to G-quadruplex structures
and, by doing so, inhibit telomerase. Structural insight into
the interactions of this compound with both intermolecular
and intramolecular G-quadruplex structures has been obtained
by one-dimensional 1H NMR molecular modeling and a photo-
cleavage assay. We also demonstrate that this compound
induces chromosomal effects and slowing of the division
of sea urchin embryos typical of G-quadruplex-interactive
compounds. On the basis of molecular modeling studies, two
additional analogues of this compound were designed and
synthesized (QQ27 and QQ28; Fig. 1B), and their interactions
with G-quadruplex structures and biological effects were ex-
amined. The maintenance or loss of biological potency paral-
leled their interactions with the G-quadruplex structure, and this
was predicted on the basis of molecular modeling.
Materials and Methods
Synthesis of Extended Fluoroquinolones (QQ58,
QQ27, and QQ28 in Figure 2)
General. All of the melting points were recorded on a Tho-
mas-Hoover capillary melting point apparatus and are un-
corrected. 1H and 13C data were obtained on a Varian Unity
300 MHz NMR spectrometer. The chemical shifts are relative
to the trace proton, carbon, or fluorine signals of the deuter-
ated solvent. Coupling constants, J, are reported in Hz and
refer to apparent peak multiplicity rather than coupling con-
stants. Mass spectroscopic experiments were performed by
the Mass Spectroscopy Center at The University of Texas,
Austin, TX. Elemental analysis of C, H, and N was done by
Desert Analytics, Tucson, AZ. Flash column chromatography
was performed on silica gel 60, 230–400 mesh, purchased
from Spectrum. All of the starting materials were obtained
from commercial sources unless otherwise specified.
Ethyl 3-(2-hydroxydibenzofuran-3-amino)-2-[(2,3,4,5,-
tetrafluorophenyl)carbonyl] Prop-2-enoate (2). A solution
of ethyl 2,3,4,5-tetrafluorobenzoylacetate (1.1 g; 4.18 mmol)
in triethyl orthoformate (1 ml; 6.06 mmol) and acetic anhy-
dride (1.8 ml; 19 mmol) was heated and stirred at 130°C for
4 h. During the process, the formed ethyl acetate was re-
moved. The mixture was then distilled under vacuum to yield
an orange oil, which was dissolved in 30 ml of dichlorometh-
ane. 3-Amino-2-hydroxydibenzofuran hydrobromide (4.07 g;
14.6 mmol), premixed with two equivalents of pyridine, was
added to the dichloromethane solution, and the mixture was
stirred overnight at room temperature. After the solvent was
removed under reduced pressure, the remaining residue was
absorbed on silica gel and subjected to flash column chro-
matography (ethyl acetate:hexane  2:1), yielding a bright
yellow powder (3.81 g; 83%). 1H NMR (CDCl3)  (mixture of
isomers; multiplet, m; singlet, s) 1.17–1.26 (m, 3H), 2.95 (s,
br, 1H), 4.10–4.25 (m, 2H), 7.05–7.20 (m, 1H), 7.33 (m, 2H),
7.43 (m, 1H), 7.52 (m, 3H), 7.85 (m, 1H), 8.69 (s, 0.7H), 8.74
(s, 0.3H); 19F NMR  156.2 (m, 1F), 154.5 (m, 0.75F),
135.4 (m, 0.25F), 140.3 (m, 0.75F), 139.4 (m, 1F), 139.3
(m, 0.25F); and MS (CI): m/z 474 (M  H).
Ethyl 1,2-difluoro-4-oxo-4H-pyrido[3,2,1-k,l ]-(3-amino-
2-hydroxydibenzofuranyl)[1,2-g]phenoxazine-5-carboxy-
late (3). Ethyl 3-(2-hydroxydibenzofuran-3-amino)-2-[(2,3,4,5,-
tetrafluorophenyl)carbonyl] prop-2-enoate (2.32 g; 4.9 mmol)
and NaH (60% in mineral oil; 0.45 g; 11.3 mmol) were mixed
with freshly distilled tetrahydrofuran and stirred at78°C for 15
min. The mixture was allowed to warm to room temperature
gradually and then heated at 65°C for 30 min. The excess NaH
was quenched by addition of 30 ml of methanol. The solution
was evaporated to dryness, and the product was purified
through flash column chromatography, yielding a yellow pow-
der (1.84 g; 89%): mp 229°C (decomposed); 1H NMR 
(CDCl3) 9.01 (s, 1H), 7.90 (d, 1H, J 7.8 Hz), 7.80 (dd, 1H, J
7.8, 2.1 Hz), 7.39 (t, 1H, J  6.9 Hz), 4.48 (q, 2H, J  7.2 Hz),
1.49 (t, 3H, J 7.2 Hz); 19F NMR133.6 (dd, 1F, J 23, 10 Hz),
1561.5 (dd, 1F, J  21, 9 Hz); and MS (CI): m/z 434 (M  H).
Ethyl (R)-1-{3-[(tert-butoxy)carbonylamino]pyrrolidin-
1-yl}-2-fluoro-4-oxo-4H-pyrido[3,2,1-k,l ]-(3-amino-2-
hydroxydibenzofuranyl)[1,2-g]phenoxazine-5-carboxy-
late (4). Ethyl 1,2-difluoro-4-oxo-4H-pyrido[3,2,1-k,l ](3-
amino-2-hydroxydibenzofuranyl)[1,2-g]phenoxazine-5-
carboxylate (0.232 g; 0.54 mmol) and (R)-3-(tert-
butoxycarbonylamino)pyrrolidine (0.302 g; 1.62 mmol)
were dissolved in 30 ml of pyridine, and the residue was
purified using flash column chromatography (dichloro-
methane:ethylacetate 2:3), yielding a yellow powder (0.27 g,
84%): mp:261°C (decomposed). 1H NMR  8.90 (s, 1H), 7.90
(d, 1H, J  7.5 Hz), 7.64 (m, 3H), 7.57 (s, 1H), 7.51 (t, 1H, J 
6.9 Hz), 7.39 (t, 1H, J 6.9 Hz), 5.35 (s, br, 1H), 4.44 (q, 2H, J
7.2 Hz), 3.70 (m, 1H), 3.61 (m, 1H), 3.40 (m, 2H), 2.29 (m, 1H),
2.00 (m, 1H), 1.49 (s, 9H), 1.46 (t, 3H, J  7.2 Hz); 19F 119.8
(d, 1F, J  13 Hz); and MS (CI): m/z 600 (M1).
(R)-1-(3-aminopyrrolidin-1-yl)-2-difluoro-4-oxo-4H-
pyrido[3,2,1-k,l]-(3-amino-2-hydroxydibenzofuranyl)[1,2-
g]phenoxazine-5-carboxylic Acid HCl Salt (5; QQ58).
Ethyl (R)-1-{3-[(tert-butoxy)carbonylamino]pyrrolidin-1-yl}-2-
fluoro-4-oxo-4H-pyrido[3,2,1-k,l]-(3-amino-2-hydroxydiben-
zofuranyl)[1,2-g]phenoxazine-5-carboxylate (0.228 g; 0.526
mmol) was mixed with 10 ml of ethanol and 3 ml 1 N KOH.
The mixture was refluxed for 30 min. HCl (9 ml of 2 N) and 6
ml of ethanol were then added to the mixture, and it was
refluxed for 4 h. After the reaction mixture was cooled down
slowly, a yellow powder was obtained by filtration, washing
with water and ethanol, and drying (250 mg, 95%): mp:
250°C (decomposed); 1H NMR (DMSO-d6) 9.24 (s, 1H),
8.49 (m, 1H), 8.12 (s, 1H), 8.05 (d, 1H, J  7.5 Hz), 7.69 (d,
1H, J  8.4 Hz), 7.54 (t, 1H, J  7.2 Hz), 7.47 (t, 1H, J  13.5
Hz), 7.40 (t, 1H, J  7.5 Hz), 3.80–4.05 (m, 5H), 2.31 (m, 1H),
2.08 (m, 1H); 19F NMR 119.1 (d, 1F, J  15 Hz); and MS
(CI): m/z 472 (M H). Anal. (C26H18N3FO5.HCl.7/4H2O) C, H,
N (Cal. C 62.09 H3.96 N8.35; Found C62.21 H3.75 N 8.13).
10 M. A. Shammas, R. B. Batchu, J. Y. Wang, L. H. Hurley, R. J. S. Reis,
and N. Munshi. Telomerase inhibition and cell growth arrest following
porphyrin treatment of multiple myeloma cells, submitted for publication.
11 The abbreviations used are: FQP, fluoroquinophenoxazine; NMR, nu-
clear magnetic resonance; CI, confidence interval; SA, simulated anneal-
ing; PIPER, N,N-bis[2-(-1-piperidino)ethyl]-3,4,9,10-perylenetetracar-
boxylic diimide; PMC, primary mesenchyme cell; VP, vegetal plate.
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Ethyl (R)-1-(3-aminopyrrolidin-1-yl)-2-fluoro-4-oxo-4H-
pyrido[3,2,1-k,l]-(3-amino-2-hydroxydibenzofuranyl)[1,2-
g]phenoxazine-5-carboxylate (6; QQ28). To a mixture of
ethyl (R)-1-{3-[(tert-butoxy)carbonylamino]pyrrolidin-1-yl}-2-
fluoro-4-oxo-4H-pyrido[3,2,1-k,l]-(3-amino-2-hydroxydiben-
zofuranyl)[1,2-g]phenoxazine-5-carboxylate (50 mg; 0.008
mmol) and methylene chloride (2 ml) was added trifluoroace-
tic acid (0.5 ml) at room temperature. After addition, the
reaction mixture was stirred at room temperature for 2 h.
Solvent was removed to give a residue and to this residue
was added methanol (5 ml) and triethylamine (0.5 ml), and the
yellow solid was collected to give a yellow powder (30 mg;
72%): mp: 210°C (decomposed); 1H NMR (DMSO-d6) 
8.79 (s, 1H), 8.05 (s, 1H), 8.03 (s,1H), 7.81 (s, 1H), 7.61 (d, 1H,
J  8.0 Hz), 7.47 (t, 1H, J  8.0 Hz), 7.36 (t, 1H, J  8.0 Hz),
7.21 (d, 1H, J 8.0 Hz), 4.23 (q, 2H, J 6.8 Hz), 3.78 (m, 2H),
3.67 (m,1H), 3.54 (m, 2H), 2.00 (m, 1H), 1.68 (m, 1H), 1.32 (t,
3H, J  6.8 Hz); MS (FAB): 500.6 (M  H); HRMS (FAB) calc.
for C28H23FN3O5 500.1622, found 500.1623; Anal.
(C28H22FN3O5.H2O) C, H, N (Cal. C64.98 H4.67 N8.12:
Found C65.10 H4.81 N7.90).
(R)-1-{3-[(tert-butoxy)carbonylamino]pyrrolidin-1-yl}-
2-fluoro-4-oxo-4H-pyrido[3,2,1-k,l]-(3-amino-2-hydroxy-
dibenzofuranyl)[1,2-g]phenoxazine-5-carboxylic acid (7;
QQ27). Ethyl (R)-1-{3-[(tert-butoxy)carbonylamino]pyrroli-
din-1-yl}-2-fluoro-4-oxo-4H-pyrido[3,2,1-k,l ]-(3-amino-2-
hydroxydibenzofuranyl)[1,2-g]phenoxazine-5-carboxylate
(100 mg; 0.17 mmol) was dissolved in methanol (6 ml), a
solution of NaOH (37 mg; 0.67 mmol) in water (3 ml) was
added, and the reaction mixture was stirred at room temper-
ature for 2 h. Methanol was evaporated off, clear solution
was neutralized with 10% HCl to pH  2.0, and precipitate
was collected and dried with a vacuum pump to give a yellow
powder (91 mg, 95%): MP: 235–237°C; 1H NMR (DMSO-d6)
 9.15 (s, 1H), 8.40 (s,1H), 8.04 (d, 1H, J  7.5 Hz), 7.94 (s,
1H), 7.66 (d, 1H, J 8.2 Hz), 7.51 (t, 1H, J 7.5 Hz), 7.39 (m,
2H), 4.12 (m, 1H), 3.95 (m, 1H), 3.89 (m, 1H), 3.77 (m, 1H),
3.56 (m, 1H), 2.11 (m,1H), 1.89 (m, 1H),1.41 (m,1H); MS
(FAB): 572.6 (M  H); HRMS (FAB) (M  H) calc. for
C31H27FN3O7 572.1838, found 572.3338; Anal.
(C31H26FN3O7.7/4H2O) C, H, N (Cal. C61.73 H4.63 N7.13;
Found C61.97 H4.50 N6.96).
Drug and Oligonucleotide Preparation. Drug solutions
were prepared as 5 mM stock solutions in DMSO and stored
at 20°C. These stock solutions were diluted to working
concentrations in distilled water immediately before use.
Oligonucleotides were synthesized on a PerSeptive Biosys-
tems Expedite 8909 automatic DNA synthesizer. The sam-
ples for NMR experiments were purified by reverse phase
high-performance liquid chromatography on a C18 column
(Dynamax-300A) and dialyzed extensively against 10 mM KCl
or 20 mM NaCl solutions followed by deionized water. Solid
supports and phosphoramadites were purchased from Glen
Research and PerSeptive Biosystems. Oligonucleotides for
polymerase extension assay and photocleavage reactions
were purified by denaturing PAGE, diluted to required con-
centrations, and dispensed into small aliquots.
Decatenation Assay. Kinetoplast DNA (0.25 g) was in-
cubated with various concentrations of QQ58 or A-62176 in
10 l of reaction buffer [50 mM Tris-HCl (pH 8.0), 120 mM KCl,
10 mM MgCl2, 0.5 mM ATP, and 0.5 mM DTT) for 10 min. Two
units of human topoisomerase II (TopoGEN Inc.) were added
to the mixture, which was then incubated at 37°C for 30 min.
The reaction was terminated with 0.1 volume of stop buffer
(5% sarkosyl, 0.025% bromophenol blue, and 50% glycerol).
The decatenation products were analyzed on 1% agarose
gels run with 0.5 g/ml ethidium bromide.
Preparation and End-labeling of Oligonucleotides for
Topoisomerase II Cleavage Reaction. DNA oligomers 5-d
[CGATGGGGAAGATCGGGCTCGTATACATTGATACGGGG-
CTCATGAGCGCTTGTTTCGGCG]-3 (A1) and 5-d[CGCC-
GAAACAAGCGCTCATGAGCCCCGTATCAATGTATACGAG
CCCGATCTTCCCCATCG]-3 (A2; Ref. 46) were synthesized
as above. The 5 end-labeled single-strand oligonucleotide
was obtained by incubating A1 with T4 polynucleotide kinase
and [-32P]ATP at 37°C for 1 h. Labeled DNA was purified
with a Bio-Spin 6 chromatography column (Bio-Rad) after
inactivating T4 polynucleotide kinase by heating for 8 min at
70°C. The labeled strand was then annealed with the com-
plementary strand (A2) and purified on an 8% native poly-
acrylamide gel.
Topoisomerase II Cleavage Reaction. The labeled dou-
ble-stranded DNA was incubated with 20 units of human
topoisomerase II in 20 l of reaction buffer [30 mM Tris-HCl
(pH 7.6), 3 mM ATP, 15 mM -mercaptoethanol, 8 mM MgCl2,
and 60 mM NaCl] at 30°C for 10 min in the presence of
various concentrations of QQ58 or A-62176. Reactions were
terminated by adding SDS to 1% of the final concentration,
and topoisomerase II was removed by proteinase K digestion
(100 g/ml) at 42°C for 1 h followed by phenol-chloroform
extraction and ethanol precipitation. Samples were loaded
onto a 12% denaturing sequencing gel. The dried gels were
exposed on a phosphor screen. Imaging and quantification
were performed using a PhosphorImager (Storm 820) and
ImageQuant 5.1 software from Molecular Dynamics.
Telomerase Assay. Telomerase assays were run as
described previously (47) using a primer extension assay
in which a 5-biotinylated primer consisting of three telo-
meric repeats was used, and the incorporation of 32P-labeled
GTP was measured. In brief, reaction mixtures (20 l)
contained 4 l of cell extracts (60 g total cell protein),
50 mM Tris-OAc (pH 8.5), 50 mM K-OAc, 1 mM MgCl2, 5 mM
BME, 1 mM spermidine, 1 M 5-biotinylated telomere primer
(TTAGGG)3, 1.2 M [-
32P]-dGTP (800 Ci/mmol), 1 mM dATP,
and 1 mM dTTP, and were incubated at 37°C for 30 min.
Reactions were terminated by adding 20 l of Streptavidin-
Dynabeads, which bind selectively to the desired targets
(5-biotinylated primer), forming a magnetic bead-target
complex. This complex was separated from the suspension
using a magnet (Dynal MPC) and washed several times with
washing buffer (2 M NaCl) to eliminate [-32P]-dGTP back-
ground. Telomerase reaction products were separated from
the magnetic beads by protein denaturation with 5.0 M
guanidine-HCl at 90°C for 30 min. After recovery of these
products, analysis was performed by 8% denaturing PAGE.
Telomerase activities were quantified by densitometric
analyses of an autoradiogram using ImageQuant software.
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All of the reactions were carried out in amber Eppendorf
tubes under subdued lighting to avoid photocleavage.
Polymerase Stop Assay. The DNA primer 5-d[TAATAC-
GACTCACTATAG]-3 and template DNA 5-d[TCCAAC-
TATGTATAC(TTGGGG)4TTAGCGGCACGCAATTGCTATA-
GTGAGTCGTATTA]-3 were synthesized and purified as
before (48). About 200 ng of the primer DNA was 5-end-
labeled with 32P using T4 polynucleotide kinase and subse-
quently purified by denaturing PAGE. The assay was carried
out as described previously (48). Briefly, 24 nM of labeled
primer and 12 nM of template DNA were annealed in a 1 
reaction buffer [10 mM Tris-HCl (pH 8.0) and 5 mM KCl] by
heating to 95°C and slowly cooled to room temperature.
MgCl2, dNTP, and Taq DNA polymerase (Boeringher-
Manheim) were added, and the mixture was incubated at
55°C for 20 min. The polymerase extension was stopped by
adding 2  stop buffer (10 mM EDTA, 10 mM NaOH, 0.1%
xylene cyanol, and 0.1% bromphenol blue) and loaded onto
a 12% sequencing gel. After electrophoresis, the gels were
dried and visualized on a PhosophorImager and quantitated
using ImageQuant software.
Photo-mediated Strand Cleavage Reaction. The se-
quence of the single-stranded DNA (G-quadruplex) used was
5-d[CATGGTGGTTT(GGGTTA)4CCAC]-3. About 400 ng of
G-quadruplex DNA was 5-end-labeled with 32P using T4
polynucleotide kinase (New England Biolabs) and subse-
quently purified by denaturing PAGE. This 5-labeled G-
quadruplex DNA was stored in Tris-EDTA buffer [10 mM
Tris-HCl, 1 mM EDTA (pH 7.5)] at a concentration of 5 ng/l
and 3000 cpm/l. For each photocleavage reaction, 30 l
of G-quadruplex DNA was mixed with 30 l of a 200 mM KCl
solution, placed in a water bath at 95°C for 4 min, and slowly
cooled to room temperature. A control set was run in distilled
water instead of KCl solution. QQ58 (6 l) at varied concen-
trations was added to each sample and transferred to a
24-well Titretek microtiter plate (ICN). This plate was placed
on top of a Pyrex glass shield and irradiated for 2 h with an
85-W xenon lamp placed under the Pyrex glass. (Pyrex glass
was used to filter the UV light under 300 nm, thereby elimi-
nating DNA damage caused directly by UV irradiation.) Dur-
ing the irradiation, the Titretek plate was rotated three times
to eliminate light heterogeneity. Reactions were terminated
by the addition of 10 g of calf thymus DNA, followed by
phenol-chloroform extraction and ethanol precipitation. The
resulting samples were subjected to treatment with 0.1 M
piperidine. The samples were then loaded onto a 16% se-
quencing gel and electrophoresed. The dried gels were ex-
posed to a phosphor screen. Imaging and quantification
were performed using a PhosophorImager and ImageQuant
software.
NMR Spectroscopy. NMR experiments were performed
on a Varian UNITY plus 500 MHz spectrometer. All of the
titration experiments were carried out at 30°C in a 90%
H2O/10% D2O solution containing 150 mM KCl, 25 mM
KH2PO4, and 1 mM EDTA (pH 7.0). A standard 1–1 echo pulse
sequence with a maximum excitation centered at 12 ppm
was used for water suppression. Thirty-two scans were ac-
quired for each spectrum with a relaxation delay of 2 s.
Two-dimensional Nuclear Overhauser Effect Spectroscopy
spectra of exchangeable protons were collected at 30°C in
time proportional phase incrementation mode with a mixing
time of 200 ms using 2048 and 1024 complex points in t2 and
t1 experiments, respectively. NMR data were processed and
analyzed using the FELIX program (Molecular Simulations
Inc.). Nearly all of the nonexchangeable DNA protons of the
5-d[A(G3T2A)3G3]-3 and 5-d[TAG3T2A]4-3 in a free form or
in a complex with ligand, except for several H5/H5 pairs,
were assigned as described (49).
Model Building and Molecular Dynamics Simulations.
The initial coordinates used in the model building process
were those published for the NMR-based model of the 1:1
PIPER:5-d[TAG3T2A]4-3 complex (49) and the antiparallel
human telomeric sequence d[AG3(T2AG3)3] (50). The neces-
sary replacements and the addition of hydrogens were car-
ried out using INSIGHT II (Ref. 51; Molecular Simulations
Inc.), and position was refined by energy minimization (1000
cycles of steepest descent and 2 1000 cycles of conjugate
gradient) while constraining the positions of heavy atoms.
Finally, the entire structure was subjected to conjugate gra-
dient minimization until convergence was reached, at which
time constraints were gradually removed. Molecular dynam-
ics simulations (100 ps) at 300 K and mechanics (2  1000
cycles of conjugate gradient minimization) were performed
using DISCOVER with the consistent force field. This struc-
ture subsequently served as the starting structure for addi-
tional energy refinement, docking, molecular dynamics, and
complex formation.
To explore the molecular interactions of QQ58 and its
analogues, QQ27 and QQ28, with the G-quadruplex struc-
tures, molecular models were built and energy minimized
using a protocol similar to that described for G-quadruplex
structures. The obtained low energy structures were manu-
ally docked into the intercalation site, and energies were
computed using the AFFINITY (52) program. To clarify the
orientation of the ligands in the intercalation site, the elec-
trostatic potentials at the van der Waals surface of the G-
quadruplex were determined by using solvent surface cal-
culations. The SA docking with 100 fs/stage duration (50 SA
stages) was then performed to find the most favorable ori-
entation. Thus, orientation with low intermolecular potential
energy was obtained while moving ligand and ligand-binding
G-tetrad residues. The resulting ligand-G-quadruplex com-
plex trajectories were energy minimized using 1000 cycles of
conjugate gradient minimizer, and the interaction energies
were computed.
Cytotoxicity Assay. Human breast carcinoma MDA-MB-
231 and prostate carcinoma DU-145 cell lines were pur-
chased from American Tissue Culture Collection (Rockville,
MD) and cultured according to the supplier’s instructions.
Exponentially growing cells (1–2  103 cells) in 0.1 ml of
medium were seeded on day 0 in a 96-well microtiter plate.
On day 1, 0.1-ml aliquots of medium containing graded
concentrations of the investigational compound were added
to the cell plates. At days 7–10, the cell cultures were incu-
bated with 50 l of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (1 mg/ml in Dulbecco’s PBS) for 4 h at
37°C. The resulting formazan precipitate was solubilized with
200 l of 0.04 M HCl in isopropyl alcohol (53). For determi-
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nation of the IC50 values, the absorbance readings at 570 nm
were fitted to the four-parameter logistic equation.
Sea Urchin Embryo Culture. Lytechinus pictus sea ur-
chins (Marinus Inc., Long Beach, CA) were maintained at
15°C in refrigerated aquaria containing Instant Ocean artifi-
cial sea water. Spawning, fertilization, drug treatment, and
embryo processing were done as described (54). Briefly, 10
min after insemination, the fertilized eggs were allowed to
settle, and the supernatant was aspirated and replaced with
fresh artificial sea water. The embryos were cultured at 18°C.
Stock solutions (10 mM) of the tested agents were prepared
in DMSO. Twenty min after fertilization, the agents were
added to 1% embryo suspensions to a final concentration of
1 M. Equivalent amounts of DMSO were added to control
egg suspensions. At measured times after insemination (10
and 24 h), the embryos were pelleted by centrifugation.
Video images of the embryos were captured with a Zeiss
standard research microscope interfaced with a Javelyn
video camera and a Panasonic time-lapse video recorder.
The nuclei were stained by the Feulgen reaction, and the
chromatin was visualized and photographed with an Olym-
pus BH2 photomicroscope equipped with fluorescence op-
tics, as described elsewhere (55).
Results
Chemistry. The synthetic procedure (Fig. 2) was based on a
published method for the synthesis of the quinobenzoxazines,
with some modification (56). The synthesis was started with
ethyl 2,3,4,5-tetrafluorobenzoylacetate (Fig. 2, 1), which was
prepared according to published procedure (5). Treatment of
2,3,4,5-tetrafluorobenzoylacetate with triethyl orthoformate in
acetic anhydride followed by 2-hydroxy-3-amino-dibenzofuran
hydrobromide generated the enamino keto acid intermediate
(Fig. 2, 2). This intermediate was treated with sodium hydride at
78°C and then heated to reflux to complete the double
annulation (Fig. 2, 3). Regioselective nucleophilic substitution of
fluoride with 3-(R)-(tert-butoxycarbonylamino)pyrrolidine was
carried out to give the key intermediate (Fig. 2, 4). Final target
molecules 5, 6, and 7 (Fig. 2) were prepared by hydrolysis and
deprotection of 4, hydrolysis of 4, and deprotection of 4,
respectively, in overall yields of 59, 59, and 44.7%, respectively.
Comparison of the Effects of A-62176 and QQ58 on
Topoisomerase II and Telomerase Activity
On the basis of our previous insights into structural re-
quirements (extended planarity, cationic interactions) for
ligand binding with G-quadruplex structures, the fluoro-
Fig. 2. Condition: (a) (i) Ac2O, CH(OC2H5)3, (ii)
3-amino-4-hydroxydibenzofuran hydrobromide; (b)
THF, NaH; (c) pyridine, (R) t-Boc-3-aminopyrroli-
dine; (d) OH/H; (e) OH; (f) CF3COOH.
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quinolones seemed to be good candidates for structural
modification. Our objective was to convert a topoisomer-
ase II poison (A-62176) to a G-quadruplex-interactive
compound. As this work progressed, a paper was pub-
lished (4) that demonstrated that quinolones were telom-
erase inhibitors, suggesting to us that quinolones might
interact with G-quadruplex structures. Our first objective
was to compare the topoisomerase II inhibitory activities
and G-quadruplex interactions of A-62176 and QQ58 to
determine whether it would be possible to separate these
activities.
Whereas A-62176 Is Both a Topoisomerase II Poison
and a Catalytic Inhibitor, QQ58 Is Only a Catalytic Inhib-
itor. Experiments were designed to compare the effects of
A-62176 and QQ58 on the activity of human topoisomerase
II. The ability to cleave and religate double-stranded DNA is
central to the physiological functions of topoisomerase II.
Kinetoplast DNA is a massive network consisting of thou-
sands of interlocked, closed circular DNA molecules called
minicircles. Topoisomerase II introduces a double-strand
break in DNA to release one minicircle from the network,
which is called a decatenation reaction (57, 58). The in vitro
effects of A-62176 and QQ58 were determined by using a
decatenation assay. As shown in Fig. 3, A and B, QQ58 had
about a 5-fold lower decatenation activity than A-62176. To
additionally characterize the properties of A-62176 and
QQ58, the contrasting effect on the DNA cleavage reaction of
human topoisomerase II of QQ58 was determined. As shown
in Fig. 3, C and D, the intensity of the topoisomerase II-
mediated cleavage at site A decreased as the concentration
of QQ58 was increased, whereas the DNA cleavage was
initially enhanced at low concentrations of A-62176 and then
decreased at high concentrations. These results show that
the two fluoroquinolones act differently on human topoi-
somerase II: QQ58 acts as a catalytic inhibitor that inhibits
the activity of topoisomerase II without trapping the cleaved
complex, and A-62176 is a topoisomerase II poison that
interferes with the breakage-rejoining reactions of topoi-
somerase II by trapping the enzyme covalent reaction inter-
mediate, known as the cleaved complex.
QQ58 Is a More Potent Inhibitor of Telomerase than
A-62176, but Is Less Potent than the Cationic Porphyrin
TMPyP4. The telomerase inhibitory activity of QQ58 was
compared with A-62176 and the cationic porphyrin TMPyP4
(Fig. 1B), a known inhibitor of telomerase because of its
ability to sequester the single-stranded DNA primer required
for the reverse transcriptase activity of telomerase into a
G-quadruplex structure (Ref. 6, 59; Fig. 4A). The IC50 values
for the inhibition of telomerase assay in the direct assay for
A-62176, QQ58, and TMPyP4 were 58, 28, and 8 M, re-
spectively. These were determined from the histogram plots
shown in Fig. 4B. It is important to note that the telomerase
Fig. 3. A, inhibition of decatenation of human topoisomerase II by QQ58 and A-62176. Catenated KDNA was treated with 2 units of human topoisomerase
II in the presence of QQ58 or A-62176 followed by SDS/proteinase K and then analyzed on agarose gel. Lane 1 contains catenated KDNA only. Lane 2
contains KDNA and topoisomerase II without compounds. Lanes 3–7 contain 2, 5, 10, 20, and 50 M of QQ58, respectively. Lanes 8–12 contain 0.5, 1, 2,
5, and 10 M of A-62176, respectively. B, intensity of decatenated KDNA was quantitated from the gel using ImageQuant software. C, autoradiogram of
a 12% denaturing polyacrylamide gel showing the topoisomerase II-mediated cleavage pattern in the presence of QQ58 or A-62176. The cleavage reaction
was done in a reaction buffer as described in “Materials and Methods.” Lane 3 contains DNA only. Lane 4 contains DNA and topoisomerase II without QQ58
or A-62176. Lanes 5–10 and 11–16 contain 0.2, 0.4, 1, 2, 5, and 10 M QQ58 and A-62176, respectively. D, strand breakage products indicated by the arrow
in C were quantitated using a PhosphorImager and ImageQuant software. The intensity of the DNA cleavage produced by QQ58 or A-62176 was determined
from the volume of the bands normalized by the total radioactivity in each lane.
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inhibitory potencies are 10-fold less than in the more fa-
miliar PCR-based telomeric repeat amplification protocol as-
say. Thus, by extension of the quinobenzoxazine fused ring
system of A-62176 (Fig. 1B) to the quinophenoxazine ring
system in QQ58 (Fig. 1B), QQ58 shows an 2-fold increase
in potency in inhibition of telomerase over A-62176, but this
is still less than TMPyP4.
Physical and Biochemical Characterization of the
Interaction of QQ58 with the Intramolecular
Antiparallel and Intermolecular Parallel
G-Quadruplex Structures
QQ58 Stabilizes an Intramolecular G-Quadruplex Suf-
ficiently to Cause Polymerase Pausing. The polymerase
stop assay (48) can be used to evaluate the interaction of
ligands with the intramolecular G-quadruplex structures. The
principle of this assay is shown in the cartoon in Fig. 5A. This
assay was originally developed to study the effect of G-
quadruplex secondary structures on polymerase processiv-
ity (60). It has also been adopted to aid in the identification of
the compounds that bind to and stabilize G-quadruplex
structures (48). QQ58 causes a sequence-specific inhibition
of Taq polymerase at the G-quadruplex site on the template
DNA (Fig. 5B). As expected, there is polymerase pausing as
the enzyme extends primer along the template, even in the
absence of QQ58 in lane 1 of Fig. 5B (attributable to the
presence of potassium in the reaction buffer that facilitates
G-quadruplex formation). However, as the concentration of
QQ58 is increased, there is enhanced pausing at the G-
quadruplex site on the template DNA (Fig. 5B). The ratio of
the intensity of the bands at the G-quadruplex pause site to
the total intensity per lane increases by 3-fold as the con-
centration of QQ58 increases from 0 to 10 M (Fig. 5C). This
indicates that QQ58 interacts with the G-quadruplex suf-
ficiently to stabilize the G-quadruplex structure and inhibit
the polymerase stop assay. In this same assay, A-62176
had little effect on the pausing of Taq polymerase at the
G-quadruplex structure site.12
1H NMR Studies Demonstrate That QQ58 Forms a Sta-
ble Complex with a Parallel-stranded G-Quadruplex in
Which the Drug Stacks at the GT Step. We chose the
d[TAG3T2A]4 intermolecular G-quadruplex (“b” in Fig. 1A) for
these studies on the basis of its relevance to the human
telomeric TTAGGG repeat and our previous success in de-
termining the solution NMR structure of its complex with
another telomerase inhibitor (49). The one-dimensional 1H
NMR spectra recorded during the titration of d[TAG3T2A]4
with QQ58 are shown in Fig. 6A. The 1H NMR signals of the
Hoogsteen-bound guanine imino protons (10–12 ppm range)
gradually disappeared during the titration, and a new set of
reciprocal upfield-shifted broadened imino proton reso-
nances appeared, as shown at the QQ58:DNA ratio of 1:1
(Fig. 6A). The more pronounced upfield shift of the G5 imino
proton relative to G4 and G3 infers that the site of QQ58
binding is between G5 and T6. Separate proton resonances
for the free DNA and the drug:G-quadruplex DNA complex
point to the slow exchange rate on the NMR time scale
between the free and bound DNA. The spectra are very
comparable with the spectra that were obtained for the ti-
tration of PIPER with the same oligonucleotide (49). These
NMR results indicate a strong and specific binding of QQ58
with parallel G-quadruplex DNA. Although attempts to obtain
a two-dimensional NOESY spectra were made, the quality of
the spectra impaired spectral assignment. The drug proton
resonances were difficult to assign despite the complete
assignment of the protons of the G-quadruplex in both the
unbound and drug-bound states. Nevertheless, the identical
changes in the DNA spectra on titration with either QQ58 or
PIPER argue for a common geometry of the drug-G-quad-
ruplex complexes. Because the structure of the PIPER-G-
quadruplex complex has already been determined (49), it
was used as a reference point for additional molecular mod-
eling studies. A proposed model of the QQ58-intermolecular
12 A. Rangan, unpublished observations.
Fig. 4. Inhibition of human telomerase by A-62176, QQ58, and TMPyP4.
A, autoradiogram showing telomerase inhibition with increasing concen-
trations of A-62176, QQ58, and TMPyP4. Lanes 1–4, 5–8, and 9–12
contain 12.5, 25, 50, and 100 M of A-62176, QQ58, and TMPyP4,
respectively. B, graphical representation of data from A.
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four-stranded G-quadruplex complex was prepared.13 The
drug molecule binds to the G-quadruplex at the GT step by
stacking of the aromatic moiety to the surface of the 3-
terminal G-tetrad. The binding site and QQ58 molecule ori-
entation in regard to DNA bases are identical to those of the
PIPER-G-quadruplex complex. This explains the similarity in
the pattern of the chemical shift changes.
QQ58 Binds to the Intramolecular G-Quadruplex Struc-
ture by Stacking between the Diagonal Loop and Exter-
nal G-Tetrad. The intramolecular basket conformation of a
monomeric G-quadruplex DNA (“d” in Fig. 1A) is likely to be
involved in the interaction with proteins and ligands in vivo (38).
To examine the interaction of QQ58 with the intramolecular
G-quadruplex structure, 1H NMR studies were carried out, with
the established basket G-quadruplex consisting of the 22-mer
human telomeric sequence d[AG3(T2AG3)3] (50). The one-di-
mensional NMR titration of 22-mer DNA with QQ58 is shown in
Fig. 6B. The spectra of the imino protons in the region of 10–12
ppm demonstrate the shift of only one particular Hoogsteen
bped guanine, namely, the G22 residue that is a part of the
G-tetrad adjacent to the diagonal loop. This suggests that the
interaction of QQ58 with intramolecular G-quadruplex is in the
proximity of this G-tetrad. The complexity of the one-dimen-
sional spectra in the imino proton region, arising because of
either strand aggregation or dynamics within the NMR time
scale used, made the interpretation of the two-dimensional
NOESY spectra rather complex. Thus, to additionally charac-
terize the intramolecular QQ58-G-quadruplex complex, photo-
cleavage studies were performed.
Photo-mediated DNA Cleavage Reactions Confirm the
Proximity of QQ58 to the External G-Tetrad. To addition-
ally characterize the binding mode of QQ58 to the intramo-
lecular G-quadruplex structures, a photo-mediated cleavage
reaction of the QQ58-G-quadruplex complex was carried
out. A DNA sequence that forms an intramolecular G-quad-
ruplex under conditions standardized previously was used
(12). The photo-reactive property of the FQPs leads to strand
cleavage in the QQ58-G-quadruplex complex in the pres-
ence of light of a specific wavelength. This in turn gives
important information about the drug localization in the com-
plex. The photocleavage pattern produced by QQ58 on the
intramolecular G-quadruplex is shown in Fig. 7A. With in-
creased concentrations of the drug, there is enhanced cleav-
age at G1, G6, and G12, which correspond to specific gua-
nines involved in the G-quadruplex. These guanines, G1, G6,
and G12, correspond to the residues that form the lowermost
G-tetrad (Fig. 7B), with G12 and G6 being the most reactive
residues. This photocleavage data confirms that the drug is
bound external to this G-tetrad. On the basis of the NMR
studies and the photocleavage experiments, a cartoon
(Fig. 7B) is proposed for the binding of QQ58 with the se-
quence that forms an intramolecular G-quadruplex structure
(Ref. 12; Fig. 7B). G12 in this structure corresponds to G22 in
the previous two-dimensional 1H NMR study, providing con-13 O. Fedoroff, unpublished observations.
Fig. 5. Inhibition of Taq poly-
merase with increasing concen-
trations of QQ58. A, cartoon of
the assay. B, autoradiogram of
the sequencing gel showing en-
hanced DNA synthesis pausing
at the G-quadruplex site with
increasing concentrations of
QQ58 (Lanes 1–7). The free
primer, the pause site, and
the full-length product are indi-
cated. C, graphical representa-
tion of the quantification of the
sequencing gel shown in B,
showing the concentration of
QQ58 to the ratio of intensity of
the bands obtained for the
pausing site/total intensity per
lane.
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firmation of the location of QQ58 in the intramolecular fold-
over G-quadruplex structure.
Molecular Modeling Predicts That QQ58 Binds to the
Human Intramolecular Telomeric Repeat d[AG3(T2AG3)3].
Docking simulations and analysis revealed that QQ58 binds
to the human intramolecular telomeric repeat d[AG3(T2AG3)3]
G-quadruplex with a binding energy of75.6 kcal/mol (Table
1A). Although this binding energy is lower than that of QQ58
with the parallel-stranded G-tetraplex (see later), the favor-
able interactions in the T2A loop suggest that it is a human
telomeric G-quadruplex-interactive agent. The aminopyrroli-
dine-NH2 is oriented to interact with G10 within the proposed
intercalation site. Furthermore, the central ring nitrogen is
positioned into the guanine carbonyl channel, and the car-
boxylic acid functional group extends into the minor groove.
The extended phenoxazine ring exhibits stacking interac-
tions with the G14 and G10 bases. This orientation was
confirmed as the most stable docking model by binding
energy calculations.
Comparison of the Biochemical and Biological
Effects of QQ58 and Its Amino (QQ27) and
Carboxyl-modified (QQ28) Analogues
On the basis of NMR and photocleavage data, initial molecular
modeling results suggested a complex in which QQ58 stacks to
the external tetrad in both the intramolecular antiparallel and
parallel G-quadruplex structures, as illustrated for the former in
Fig. 7B. Molecular modeling was carried out on the human
telomeric antiparallel (Fig. 8A) and parallel-stranded (Fig. 8B)
G-quadruplex structures with QQ58 to gain additional insight
into these structures, and on the basis of the results from the
parallel-stranded G-quadruplex, two synthetically accessible
molecules (QQ27 and QQ28 in Fig. 1B) were designed and
synthesized, which were predicted to effect specific H-bonding
interactions between the FQP and the G-quadruplex
structures, resulting in much less favorable interactions
of QQ28 with the intermolecular parallel-stranded G-
quadruplex structure than either QQ27 or QQ58. A parallel
series of biochemical and biological experiments were
carried out to test these ideas.
Molecular Modeling Predicts That QQ58 Has a Higher
Binding Interaction with the G-Quadruplex Structure.
Molecular modeling and SA docking experiments revealed that
QQ58 exhibited the highest binding interactions with the four-
stranded parallel G-quadruplex (d[TAG3T2A]4; Table 1B) and is
intercalated at the G5-T6 nucleotide step approximately be-
tween two pairs of guanines and thymines, with the positively
charged side chain located in the groove (Fig. 8B). A strong
intermolecular hydrogen bond interaction of the N7 atom of G5
with the carboxylic proton of QQ58 (N7 to COOH is 2.38 Å) was
observed (Fig. 8C). The QQ58 aminopyrrolidine amino group
takes part in a hydrogen bonding interaction with the 5 phos-
phate group of G5 (Fig. 8C). QQ58 also shows favorable stack-
ing interactions between the G5 guanine tetrad and two of the
6-thymine residues. These electrostatic (167.5 Kcal/mol) and
van der Waals (96.4 Kcal/mol) interactions give rise to a cal-
culated binding energy of 86.4 Kcal/mol (Table 1B). In the
case of compound QQ28, such interactions were not observed,
presumably because of the strong steric clash of the tert-
butoxy carbonyl group of the aminopyrrolidine with G5 at the
intercalation site. This in turn leads to the shift of the carboxylic
acid functionality from its H-bonding site at G5. Analysis of all of
the dynamic trajectories reveals that the tert-butoxy carbonyl
group is rigidly positioned and oriented. This results in dramatic
loss of both electrostatic and van der Waals energies relative to
QQ58. Similarly, the presence of an ethyl ester group in the
case of QQ27 restricts the electrostatic and hydrogen bonding
interactions with the G5 nucleotide region of the intercalation
site but to a much lesser extent than in QQ58. The calculated
binding energies for QQ27 and QQ28 with the parallel-stranded
complexes are 26.5 and 112.6 Kcal/mol, respectively.
Fig. 6. Effect of QQ58 on the 1H NMR spectra of G-quadruplex struc-
tures. A, one-dimensional 1H NMR titration of d[TAG3T2A]4 with QQ58 to
obtain a 1:1 QQ58:DNA ratio. The imino proton and aromatic proton
regions of the 500 MHz NMR spectra are shown with increasing amounts
of ligand added at 30°C. G3, G4, and G5 represent the imino proton
resonances of the free DNA, whereas G3*, G4*, and G5* represent the
imino proton resonances of the ligand-bound DNA. B, one-dimensional 1H
NMR titration of d[AG3(T2AG3)3] with QQ58 to obtain a 1:1 QQ58:DNA
ratio. The imino proton regions of the 500 MHz NMR spectra are shown
with increasing amounts of ligand added at 30°C. The arrow points to the
imino proton resonance of G22, which shifts on addition of QQ58.
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The Polymerase Stop Assay Demonstrates That QQ28
Has Only a Minimal Stabilizing Effect on G-Quadruplex
Structure, Whereas QQ27 Has an Intermediate Effect.
On the basis of molecular modeling results, we predicted that
the steric bulk of the N-Boc group on the aminopyrrolidine of
QQ28 should interfere with intercalation into the G-quadruplex
structure and prevent any ionic interaction between the posi-
tively charged amino group of QQ28 and the anionic backbone
of DNA. However, the ethyl ester of QQ58 should not dramat-
ically affect the binding of QQ27. A polymerase stop assay was
used to evaluate the comparative abilities of QQ58, QQ27, and
QQ28 to stabilize the intramolecular fold-over G-quadruplex
structure. The results shown in Fig. 9, A and B, demonstrate
that, as predicted, QQ58 and QQ27 have approximately the
same potency in inhibition of the Taq polymerase, whereas
QQ28 was much less potent.
Comparative Cytotoxicity Measurements of QQ58,
QQ27, and QQ28 Demonstrate That QQ58 and QQ27 Are
More Potent Than QQ28. The IC50 values of QQ58, QQ27,
and QQ28 were determined against human breast and pros-
tate carcinoma tumor cell lines. As shown in Table 2, the
cytotoxicity in both cell lines followed the same pattern, with
the IC50 potency values increasing in the order QQ28 
QQ27  QQ58. For QQ28 and QQ58, the cytotoxicity in
DU-145 was higher than in MDA-MB-231. We have observed
a similar high sensitivity to other quinolones in DU-145 cells
in comparison with MDA-MB-231.14
The Antiproliferative and Chromosomal Effects of
QQ58, QQ27, and QQ28 Show That QQ58 and QQ27 Are
More Potent Than QQ28. Nonmammalian organisms are
attractive supplements to conventional in vivo models, be-
cause the key cellular pathways are conserved throughout
the animal kingdom. We have examined early stage sea
urchin embryos as a novel in vivo model that allows rapid
assessment of drug effects over many cell cycles in much
less time than in other animal models or in cultured human
tumor cells. To date we have evaluated the in vivo effects of
anticancer agents from diverse groups, such as alkylators,
DNA-interactive natural products, and telomere- and telom-
14 E. Izbicka, manuscript in preparation.
Table 1 Computed interaction energies (kcal/mol)
A. Energies for QQ58 human telomeric repeat d[AG3(T2AG3)3] G-quadruplex
Ligand
d[TAG3T2A]4-
ligand VdW
energy
d[TAG3T2A]4-
ligand electrostatic
energy
d[TAG3T2A]4-ligand
total energy
Ligand VdW
energy
Ligand
electrostatic
energy
Ligand total
energy
Calculated
binding
energy
QQ58 62.7 176.1 238.8 78.9 84.3 163.2 75.6
B. Energies (kcal/mol) for QQ58-, QQ28-, and QQ27-parallel-stranded G-quadruplex (d[TAG3T2A]4) complexes
Ligand
d[TAG3T2A]4-
ligand VdW
energy
d[TAG3T2A]4-
ligand electrostatic
energy
d[TAG3T2A]4-ligand
total energy
Ligand VdW
energy
Ligand
electrostatic
energy
Ligand total
energy
Calculated
binding
energy
QQ58 96.4 167.5 263.9 61.3 116.2 177.5 86.4
QQ28 89.2 253.4 342.6 92.5 137.5 230.0 112.6
QQ27 116.1 178.1 294.2 69.3 198.4 267.7 26.5
Fig. 7. QQ58 photo-mediated strand cleavage
reaction of intramolecular G-quadruplex. A, auto-
radiogram of a photocleavage sequencing gel
with increasing concentrations of QQ58. Lanes 1
and 2 are the AG/TC Maxam-Gilbert sequencing
reactions, and Lanes 4–8 are increasing concen-
trations of QQ58 (1–25 M). The enhanced cleav-
age sites are indicated by G1, G6, and G12. G7 is
in the same tetrad but is not cleaved excessively.
B, diagrammatic representation of the proposed
external binding of QQ58 to the G-quadruplex
below the lower-most G-tetrad based on the pho-
tocleavage results with the ligand.
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erase-interactive agents, including a telomere mimic. We
determined the effects of these agents on cellular prolifera-
tion using a new quantitative assay and on chromosome
morphology. The specific and reproducible effects of many
of these drugs correlated with the detection of similar effects
in tumor cells (54, 55, 61–63).
In this study, we evaluated the in vivo effects of 1 M of
QQ28, QQ27, and QQ58 in developing sea urchin embryos.
Preliminary dose-dependence tests have shown that these
concentrations are subtoxic and compatible with the assays.
Antiproliferative effects of the agents were assessed by ex-
amining the morphology of the embryos cultured for 10 and
24 h in the presence of the three quinolones. Photomicro-
graphs (Fig. 10A) show that at 10 h all of the embryos are still
within fertilization coats. The control group and QQ28-
treated embryos appear normal with well-defined blasto-
coels. Cleavage is delayed in QQ27- and QQ58-treated em-
bryos, so there are fewer cells, and a blastocoel has not yet
formed. At 24 h (Fig. 10B) all of the embryos have hatched
and are swimming, which suggests lack of major toxicity of
the examined compounds. The control group and QQ28-
treated embryos appear normal with well-defined blasto-
coels into which PMCs have ingressed at the vegetal pole
(seen as the thicker layer of cells in the bottom of the em-
bryos). Invagination of the vegetal pole has begun in the
control group and the QQ28-treated embryos. Because of
the cleavage delay in the QQ27- and QQ58-treated embryos,
the embryos are smaller and there are fewer cells. Addition-
ally, the blastocoels appear to be abnormally filled with cells,
and there does not appear to be a concentration of PMCs at
a well-defined vegetal pole. The antiproliferative effect of
QQ58 is apparently greater than that of QQ27, and this
difference is more noticeable at 10 h than at the later time
point at 24 h.
Fig. 8. Molecular modeling of the d[AG3(T2AG3)3]-QQ58 (A) and d[TAG3T2A]4-QQ58 (B and C) complexes. A, structure of the d[AG3(T2AG3)3]-QQ58
complex in the final model after energy minimization. The G-quadruplex structure is shown as a stick model with compound QQ58 in color by atom type
Corey-Pauling Koltun model. The proposed intercalation sites (yellow) are labeled. B, structure of the d[TAG3T2A]4-QQ58 complex in the final model after
energy minimization. Coloring is as in A. C, stereo representation of the proposed binding mode of QQ58 in complex with parallel-stranded G-quadruplex
shown in color by atom type. The white dotted lines show the hydrogen bonding distances in Å. The G-quadruplex complex is clipped to afford a better
view of the intercalation site.
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Chromosome-specific effects of the agents were deter-
mined using high-power fluorescence microscopy. Al-
though a single focal plane is exceeded at magnifications
greater than 400, resolution of mitotic chromosomes in
all phases of mitosis is possible. Both the nuclei and
chromosomes may be visualized in bright red over a dark
background with fluorescence optics (green excitation),
with very little photobleaching. We have used this method
to assess chromosome-specific effects of QQ28, QQ27,
and QQ58 in 10-h embryos cultured in the continuous
presence of the compounds. The 10-h embryos have been
chosen as more representative than the 24-h ones be-
cause at 10 h the embryos are actively dividing and there
is the most chromosomal activity. Fig. 11 (top left panel)
shows representative mitotic chromosomes in a control
(nontreated) embryo at 10 h after fertilization. The con-
densed mitotic chromosomes stain more deeply than the
less condensed interphase nuclei in the background.
Many metaphase chromosomes are observed in typical
linear arrangements on metaphase plates. During an-
aphase the chromosomes separate and move to opposite
poles cleanly with very little “tailing” of chromosome arms
on the mitotic spindle. Telophase chromosomes are ob-
served as two small, dense concentrations of mitotic chro-
mosomes at opposite poles, where they will decondense
into interphase nuclei. As additionally shown in Fig. 11, not
only the control but also QQ28-treated embryos show the
normal “tight” mitotic chromosomes among a larger num-
ber of nuclei. On the other hand, the QQ27- and QQ58-
treated embryos show a reduced number of nuclei, con-
sistent with a growth delay. The nuclei are larger and more
diffuse. The mitotic chromosomes are more diffuse and
segregate abnormally, often to multiple poles, and end-
to-end fusions are often observed. These results are con-
sistent with the cleavage delay, and fewer cells are seen in
the live embryos.
Discussion
In this study we have identified a new structural motif for
a ligand with G-quadruplex interaction that results in bio-
logical effects associated with G-quadruplex-interactive
compounds. The initial lead compound was a quinoben-
zoxazine, which derived its structural origin from the well-
known fluoroquinolone antibiotics (see Fig. 12), typified by
norfloxacin. Researchers at Abbott Laboratories, Abbott
Park, IL demonstrated that this quinobenzoxazine com-
pound could be converted into a mammalian cytotoxic
agent by expansion of the dicyclic quinolone to the tetra-
cyclic quinobenzoxazine (A-62176), which was shown to
be a topoisomerase II poison (64). The same structural
elements (planarity, amphoteric nature) can then be used
as a basis to design an even more expanded ring system
(quinophenoxazine) that is now a G-quadruplex-interac-
tive drug (QQ58) that causes biological effects associated
with G-quadruplex-interactive compounds.
Comparison of Complexes of A-62176 and QQ58 with
the Topoisomerase II-DNA Complex and the G-Quadru-
plex Structure. Whereas both norfloxacin and A-62176 tar-
get gyrase and topoisomerase II-DNA complexes to produce
poisoned complexes in which these drugs stabilize the co-
valently linked protein-DNA complexes, QQ58 has lost this
property (see Fig. 3) but is instead able to recognize and bind
quite specifically to G-quadruplex structures. The quinoben-
Table 2 Cytotoxicity of novel quinolones against human tumor cell
lines
Compound
IC50 (M)
MDA-MB-231 DU-145
QQ58 0.15 0.07
QQ27 1.25 1.86
QQ28 20 5.77
Fig. 9. Differential effects of QQ27, QQ28, and QQ58 on DNA synthesis
arrest by G-quadruplex structure. A, autoradiogram of the sequencing gel
showing Taq polymerase primer extension arrest at the G-quadruplex site
in the presence of QQ58, QQ27, and QQ28. Lanes G, C, A, and T are DNA
sequencing lanes. B, quantitation of the sequencing gel shown in A. The
drug concentrations are plotted against the normalized ratios of the band
intensity of the G-quadruplex pause site and the band intensity of the
full-length product.
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zoxazine molecule A-62176 requires divalent cations such as
Mg2 to form a stable complex with DNA, and we have
proposed a 2:2 drug:Mg2 model for the complex with both
duplex DNA and the topoisomerase II-DNA complex (65). In
contrast to this requirement for divalent cation, the FQP does
not require metals for its interaction with either the intra- or
intermolecular G-quadruplex structure, and we have more
direct and precise structural information on the structure of
the complex in which only one molecule of the FQP binds to
a single G-quadruplex molecule, in contrast to the two in the
model of the A-62176-DNA–topoisomerase II complex (65).
It seems likely that QQ58, like A-62176, will bind nonspe-
cifically by an intercalative mechanism to duplex DNA, i.e.,
similar to that in which divalent cations are not involved. An
important objective is to design G-quadruplex-interactive
compounds belonging to the FQP group that clearly differ-
entiate between duplex and G-quadruplex DNA.
Molecular Recognition of the G-Quadruplex Structure
by QQ58. Despite the contrasts in the molecular targets
(duplex topoisomerase II versus G-quadruplex structures) of
A-62176 and QQ58, there are common molecular features of
both molecules that appear critical for recognition of unique
features of the two different receptors. These are the am-
photeric nature of both molecules, the intramolecular sepa-
ration distance of the positive and negative charges, and the
planar nature of both the quinobenzoxazine and FQP mole-
cules. For the FQP molecule QQ58, the carboxylic acid and
amino group of the pyrrolidine are both involved in donor-
acceptor interactions with N7 of guanine in the external
tetrad and the anionic backbone of the G-quadruplex struc-
ture, respectively. The charge separation of the amphoteric
groups on QQ58 is precisely that required for in-register
interaction with the complementary groups on the G-quad-
ruplex structure. This observation provides the insight into
why even norfloxacin shows some modest telomerase inhi-
bition. However, because norfloxacin and A-62176 have
minimal stacking interactions within the G-tetrad-thymine
step of the G-quadruplex structures, there is presumably
insufficient - interaction to adequately stabilize the com-
plex. The relative importance of the charge-charge interac-
tions and the stacking is illustrated by the comparative mod-
eling and biological studies of QQ58, QQ27, and QQ28.
Whereas steric disruption of the two in-register donor-
acceptor pairs in the QQ28-G-quadruplex interactions al-
most completely eliminates G-quadruplex binding and bio-
logical activity, the sterically tolerated ethylester of QQ27 still
permits one of two H-bonds and may partially make up for
the post-electrostatic interactions by increasing the van der
Waals interactions, thus permitting residual G-quadruplex
binding and biological activity that is almost as good as
QQ58. Most important, our QQ58-G-quadruplex model,
which is based on 1H NMR and photocleavage data, along
with molecular modeling, accounts fully for the modulation of
Fig. 10. Effects of FQPs on proliferation dynamics of early sea urchin
embryos. The embryos were cultured in the presence of FQPs or DMSO
(control) for 10 h (A) or 24 h (B), pelleted by centrifugation, and video
micrographed as described in “Materials and Methods.” A, 10 h: the thin
surrounding coat elevated away from the surface of the embryo is the
fertilization coat (FC), which is present in all embryos. The thick layer
below the FC is the cellular layer of the early blastula embryo. At 10 h,
there are 400–500 cells in it. These layers are fully formed in control and
QQ28-treated embryos. There are fewer and larger cells in the QQ27- and
QQ58-treated embryos, so the layer is thicker and not fully formed. The
cellular layer surrounds the blastocoel, the fluid-filled cavity of the early
embryo into which cells of the cellular layer will move during the formation
of the larval gut. B, 24 h: no FCs are present in any of the embryos. This
demonstrates that toxicity is not found at 1 M because to hatch out of the
FCs the embryos must synthesize a specific protease, hatching enzyme
that degrades the FCs. Hatching occurs at 15 h in these embryos. In
addition, all embryos produce cilia and begin to swim at the normal time,
shortly before hatching, thus demonstrating their viability, although there
are fewer cells in the QQ27- and QQ28-treated cells. In control and
QQ28-treated embryos, development is normal. There is a thin cellular
layer composed of 1000 cells that surrounds the blastocoel. Cells from
the cellular layer have moved into the blastocoels. They are the PMCs. At
7:00 in the control embryo and at 9:00 in the QQ28-treated embryo the
cellular layer has begun to invaginate to form the larval gut. At this stage
it can be labeled the VP. In the QQ27- and QQ58-treated embryos, cell
division has proceeded since 10 h, and there are obviously more cells.
However, the embryos lack definitive blastocoels because cells seem to
abnormally fill the blastocoels. Well-organized PMCs and obvious VPs are
not present, although the thickened, flattened cellular layer in the QQ58-
treated embryo at 3:00 could be a VP.
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activity of QQ27 and QQ28 and also provides an important
starting point for the design of more potent compounds.
Biological Effects of the FQPs. The three quinolones
QQ28, QQ27, and QQ58 examined in this study exhibit dif-
ferent modes of interaction with G-quadruplexes and effects
on topoisomerase II activity. Interestingly, QQ28, which nei-
ther interacts with G-quadruplex nor poisons topoisomerase
II, showed the lowest cytotoxicity in two model human tumor
cell lines in vitro and had no major antiproliferative effect on
developing sea urchin embryos in vivo. The G-quadruplex-
interactive compounds QQ58 and QQ27, which do not poi-
son topoisomerase II, showed increased cytotoxicity in hu-
man tumor cells and sea urchin embryos. In both systems,
the antiproliferative effects of QQ58 were more potent than
those of QQ27.
Although QQ27 and QQ58 significantly delayed growth of
the embryos at the early stages, the development of the
embryos was not largely impaired, which is consistent with a
lack of major cytotoxic effects. Under subtoxic conditions,
we were able to observe chromosome end fusions induced
only by these compounds. The chromosomal abnormality
exhibited specifically by embryos treated with QQ27 and
QQ58 is an apparent end-to-end adherence of anaphase and
telophase chromosomes. The end-to-end adhesions are
manifested in the form of anaphase chromosomes that often
extend from pole to pole of the mitotic spindle. These effects
are very similar to the chromosomal fusions that result from
a mutation in the telomerase template in Tetrahymena (66)
and a dominant negative mutation in the telomere binding
protein TRF2 in HTC75 cells (67).
The end-to-end adherence of chromosomes is observed in
embryos treated with structurally dissimilar telomere- and
telomerase-interactive agents designed to target very differ-
ent sites in the telomere-telomerase complex. We have
Fig. 11. Chromosomal effects
of FQPs in early sea urchin em-
bryos. The embryos were cul-
tured in the presence of FQPs or
DMSO (control) for 10 h and pel-
leted by centrifugation. The nu-
clei were stained by Feulgen re-
action and the chromatin was
visualized as described under
“Materials and Methods.” Chro-
mosomal bridges are marked
with arrows.
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found that the G-quadruplex-interactive porphyrin TMPyP4
showed the most potent chromosome destabilizing proper-
ties with no significant inhibition of DNA synthesis (54). Be-
cause the isomeric porphyrin TMPyP2, which does not show
stacking interactions with G-quadruplex, has not demon-
strated similar effects in sea urchins and other systems ex-
amined to date, the telomere effects of TMPyP4 might be
related to stabilization and/or de novo formation of G-quad-
ruplex in cells. This specific chromosomal effect has also
been induced by an oligonucleotide telomere mimic but not
the scrambled sequence (54), and by other agents, of which
the mechanisms of action might involve regulation of te-
lomere maintenance (62, 63).
By analogy, the chromosome destabilizing activity of
QQ27 and QQ58 suggests that these compounds might also
affect telomere integrity. The results suggest that the G-
quadruplex interactions are linked with the ability of FQP to
induce chromosome destabilization. Poisoning of topoi-
somerase II does not apparently play a role in the process,
because QQ58 and QQ27, which do not poison topoisomer-
ase II, stimulated end-to-end adherence of chromosomes.
We have demonstrated15 that the quinolones can stabilize,
but do not stimulate, de novo formation of G-quadruplex.
Thus, the present results imply that G-quadruplex-like struc-
tures may well exist in vivo. Additional investigation of this
issue is warranted.
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